Kornimate/medical-research-clean huggingface dataset:
scenario-based simulation

Conditions: Simulation

Summary: the aim of this study is to determine the effect of scenario-based simulation on clinical learning, confidence and satisfaction of midwifery students in management of eclampsia crisis in labor

hypotheses 01; there was no difference between the clinical learning score of the experimental group and the pain score of the control group. h02; there was no difference between the confidence score of the experimental group and the confidence score of the control group. h03; there was no difference between the satisfaction score of the of the experimental group and the satisfaction score of the control group. the study will be carried out in two different groups. the practice will start with meeting the students. after the students are evaluated in terms of eligibility criteria for the research, the students who are eligible will be informed about the research and written informed consent will be obtained from the students who accept. the random distribution of students to the study groups will be carried out using the block randomization method. the following applications will be made to the groups. eclampsia crisis in labor training will be given by the responsible investigator, and then one of the groups separated by randomization will perform eclampsia crisis in labor first care on the second group model using high reality simulator. these trainings will first be in the form of the instructor responsible for the groups demonstrating the application, and then the students will apply it one by one

Eligibility criteria:
inclusion criteria: * volunteer to participate in the study * take the obstetric emergencies course exclusion criteria: * not volunteering to participate in the study * not taking the obstetric emergencies course
facial hair, ppe and covid-19

Conditions: COVID; Safety Issues

Summary: an observational cross sectional questionnaire study looking into facial hair of hospital doctors during the covid-19 pandemic, and how personal protective equipment guidance has affected this.

covid-19 is a highly contagious virus which has caused a global pandemic. there have been significant health consequences for healthcare workers, which may be related to the provision of personal protective equipment (ppe). following ppe guidance is a significant health and safety concern, under which facial hair guidance for tight fitting masks falls. this has implications as ffp3 masks are not the only form of ppe for the face, and this study may highlight a need for employers to diversify which ppe they supply to their employees, such as full hoods if staff need to maintain facial hair for cultural or religious reasons. as such, facial hair has potential implications for patient safety, but also these have to be balanced with personal or religious reasons for maintaining facial hair. our study aimed to determine the facial hair styles of hospital doctors, and reasons for maintaining them during the covid-19 pandemic. we also looked at whether these styles adhered to the ppe guidance set about by public health england (phe)

Eligibility criteria:
inclusion criteria: all hospital doctors working at the main site at royal cornwall hospital between january and april 2020 were included in the study population. this includes all genders and ethnicities. exclusion criteria: the principle exclusion criteria were those who did not work at the royal cornwall hospital main site. also, while not forming part of the exclusion criteria, those who are unable to grow facial hair were excluded from the statistical analyses.

Keywords: facial hair beard personal protective equipment
transitions of care clinic (tocc)

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: the transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital. patients at the highest risk include older adults and patients with low health literacy, socioeconomic disadvantages, and/or multiple comorbidities. this project proposes to expand the existing transitions of care clinic (tocc) which was recently introduced in our institution in 2024, to bridge the gap in care between hospital discharge to home and connect discharged patients to their outpatient providers with a focus on patients with heart failure (hf). the existing tocc, a multidisciplinary team composed of a pharmacist and a nurse practitioner, seeks to improve the services that are currently being provided to patients and enhance the transitions of care process by providing patients with education, tools, and resources to help manage their chronic disease. with this study, we propose to expand tocc by offering extensive education to patients via ipad videos and providing them with hf tool kits prior to their discharge. we will also assist with scheduling follow appointments with their outpatient providers and follow up with patients after the appointment takes place to re-evaluate their needs and reinforce self management of heart failure. by targeting patients being treated for acute exacerbation of heart failure with preserved ejection fraction (hfpef), this study aims to facilitate the transition of care, reduce hospital readmissions and improve patients' quality of life and satisfaction. patients with hfpef represent a majority of the hf patients that are readmitted at oumc. hfpef patients have fewer guideline recommended treatments and represent a vulnerable patient population. the hf tool kits will provide these patients with the essential tools, resources, and log sheets for self-management such as monitoring daily weights, monitoring blood pressure and heart rate. patients provided with a kit will receive an initial phone call from tocc within 1 to 3 days of discharge and a second phone call within 21-24-days post discharge.


Eligibility criteria:
inclusion criteria: * adults ages 18 to 90 years old discharged from ocean university medical center (oumc) * inpatient admission for heart failure with preserved ejection fraction (hfpef) exacerbation * patient discharged home exclusion criteria: * refuse to participate in tocc phone calls * discharged to a facility * discharged with homecare services * discharged on hospice services * hemodialysis * leave against medical advice (ama) * pregnant * diagnosed with dementia * without medical capacity or unable to provide own consent

Keywords: discharge plans heart failure with preserved ejection fraction readmissions transition of care
pharmacological effect of carica papaya leaves mother tincture in healthy individuals blood parameter

Conditions: Dengue

Summary: aims \& objectives to evaluate the effectiveness of administering of carica folia mother tincture to healthy individual's platelet count. sample details:- students, doctors and non-teaching staffs of father muller homoeopathic medical college are taken up for the study. a minimum of 60 persons will be selected and will be divided into two groups, control \& experiment by lottery method. voluntary participation in the study is expected. 30 persons in each group. one group will receive carica folia mother tincture and other group will receive placebo. complete blood count including platelet count will be measured for all 60 subjects before commencing the study. the drug namely carica folia mother tincture will be procured from father muller homoeopathic pharmaceutical division which compiles with the standards of homoeopathic pharmacopeia of india. daily dosage -30 drops of carica folia mother tincture in 30 ml of distilled water morning and night for 3days. on 4th day complete blood count including platelet count will be estimated for all 60 subjects. research methodology and statistics: pre \&post with control design is done. data from the sample is collected and is subjected to paired 't' test and unpaired 't' test. hypothesis:- null hypothesis: no significant changes in complete blood count and platelet count before and after the intervention. alternate hypothesis: there is significant variation in complete blood count and platelet count before and the intervention.


Eligibility criteria:
inclusion criteria: * healthy individuals * age group- 18yrs to 25yrs * both sexes * free from any type of medicinal agent at least 15 days before commence the intervention. exclusion criteria: * person suffering from any illnesses * age group below 18yrs and above 25yrs. * person taking any medicinal agents, vitamins or any kinds of supplements will not be considered as subject.
iatrogenic atrial septal defect study (iasd)

Conditions: Septal Defect, Atrial

Summary: this is an open-label, randomized, controlled trial of iatrogenic atrial septal defect closure with the an atrial septal occluder versus usual care observation in patients post-mitral valve intervention requiring large bore transspetal access.

this study is an open label, prospective, multicenter, non-randomized single-arm study to evaluate the safety and efficacy of the closing iatrogenic atrial septal defects in patients undergoing transcatheter mitral valve procedures using large sheaths. a maximum of 5 clinical sites (referred to as "sites" in the remainder of this document) in the u.s. two hundred and ten patients will be enrolled in this study. the patients will randomized 1:2 device: control. the anticipated accrual rate is approximately 20 subjects per month for a total accrual period of approximately 12-18 months. patients may be enrolled into the study provided all inclusion and no exclusion criteria are met as specified in section 4. subjects will be evaluated through hospital discharge and return for follow-up visits at 30 days, 6 months, and 12 months.

Eligibility criteria:
inclusion criteria: 1. age ≥18 at the time of informed consent signature. 2. capable of complying with protocol requirements, including follow-up. 3. an informed consent form signed by subject or legal representative. 4. patient has had successful reduction of mitral regurgitation to at most moderate regurgitation post-mitral-clip. exclusion criteria: 1. remaining mitral regurgitation of ≥ moderate-severe 2. subject unable or unwilling to provide informed consent 3. concomitant severe aortic valve disease 4. dialysis 5. pregnancy or intent to become pregnant 6. life expectancy \< 1 year 7. active bleeding 8. inability to follow up with 6-month timepoint due logistical concerns

Keywords: mitral valve intervention iatrogenic septal defect
a phase 1b/2 study of amg 655 in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: part 1 is complete. part 2 is a multi-center, randomized, double-blind, placebo-controlled, phase 2 segment that will commence upon identification of the maximum tolerated dose in part 1. the primary objective of part 2 of the study is to estimate efficacy in combination with carboplatin and paclitaxel. subjects will be randomized at a 1:1:1 ratio to 1 of 3 treatment arms. subjects in each of the 3 arms will receive up to 6 cycles of paclitaxel/carboplatin (at the same dose and schedule in part 1) in combination with either amg 655 at the maximum tolerated dose (arm 1), amg 655 at a lower dose (arm 2), or amg 655 placebo (arm 3) iv q3w. randomization will be stratified by ecog (0 or 1) and disease stage (iiib or iv/recurrent).


Eligibility criteria:
inclusion criteria: * disease related * histologically or cytologically confirmed non-small cell lung cancer. * subjects must have advanced non-small cell lung cancer defined as stage iiib with malignant pleural effusion or stage iv or recurrent disease. * planning to receive up to 6 cycles of chemotherapy * eastern cooperative oncology group (ecog) score of 0 or 1 demographic * men or women \> 18 years of age ethical * adequate hematological, renal, hepatic and coagulation function general * plan to begin protocol specific therapy \< 7 days after enrollment/randomization exclusion criteria: * disease related * untreated or symptomatic central nervous system metastases. subjects with a history of brain metastases are eligible if definitive therapy has been administered (surgery and/or radiation therapy), there is no planned treatment for brain metastasis and the subject is clinically stable and off corticosteroids for at least 14 days before enrollment/randomization. * prior chemotherapy as follows: * any prior chemotherapy for advanced non-small cell lung cancer * any prior adjuvant chemotherapy for non-small cell lung cancer \ 52 weeks prior to randomization is permitted. * any prior chemoradiation. * central (chest) radiation therapy \< 28 days prior to randomization, radiation therapy for peripheral lesions \< 14 days prior to enrollment/randomization * other abnormal medical conditions * documented myocardial infarction or unstable/uncontrolled cardiac condition * history of arterial thrombosis, pulmonary embolus, deep vein thrombosis or hemorrhagic disorders * major surgical procedure \< 30 days prior to enrollment/randomization or not yet recovered from prior major surgery, minor surgical procedure \< 7 days prior to enrollment/randomization or not yet recovered from prior minor surgery

Keywords: nsclc non-small cell lung cancer paclitaxel carboplatin amg 655
cancer ratio,pleural fluid adenosine deaminase,lactate dehydrogenase, interferony, tumor necrosis factor,and interleukins{2,12,18}for differentiation between malignant and non malignant pleural effusion

Conditions: Pleural Effusion, Malignant

Summary: to evaluate the ability of cancer ratio and pleural fluid markers to discriminate between malignant and non malignant effusion

pleural effusion is a common clinical entity affecting approximately 1.5 million patients per year in the united states. {3.1}a large number of diseases may be associated with pleural effusion. this includes: * local conditions affecting the pleura (eg, tuberculous pleurisy, pleural mesothelioma), * extrapulmonary diseases with secondary pleural involvement (eg, chronic heart failure, liver cirrhosis). to date, differentiation between both types of pleural effusion (exudate and transudate) is the most common initial diagnostic approach for patients with pleural effusion. exudative effusion is commonly seen in three conditions namely cancer (mpe), tuberculosis (tb) and para pneumonic although mpe can be diagnosed by simple pleural fluid cytology, this method has significant limitations, including a highly variable sensitivity, ranging from as low as 11.6% to as high as 71%. in contrast to other common causes of pleural effusion such as t.b, no accurate biomarkers of mpe have been established. several tumor markers were extensively evaluated, including carcinoembryonic antigen, cytokeratin-19 fragments, and cancer antigen 125, but none of them were found sensitive and specific enough to be implemented in routine clinical practice

Eligibility criteria:
inclusion criteria: * patients (100 cases) with exudative pleural effusion who will be admitted to department of chest diseases and tuberculosis, assiut university hospital exclusion criteria: * age ˂ 18 years * refusal to participate in the study
extra-cochlear electrode placement at the post-auricular vagus nerve in cochlear implantation

Conditions: Hearing Loss

Summary: this study will evaluate hearing outcomes after cochlear implantation with placement of the ece1 ground electrode near the post-auricular vagus nerve (arnold's nerve) to assess non-inferiority with respect to placement under the temporalis muscle.


Eligibility criteria:
inclusion criteria: * will be undergoing surgery for a cochlear implant from cochlear americas * is willing to participate in the study exclusion criteria: * has history of prior ear surgery, congenital ear malformation, or prior cochlear implantation in the ear to be implanted * pregnant, planning to become pregnant, or breastfeeding patients cannot undergo the standard-of-care implantation procedures required for participation in the study.
different susceptibility to sars cov-2 infection among health care workers highly exposed to covid-19.

Conditions: Health Care Worker Patient Transmission; Receptor Site Alteration; Susceptibility, Disease; Immune Response

Summary: the primary objective of this study is to establish differences in susceptibility to sars cov-2 infection among health care workers (hcw) highly exposed to patients with covid-19 diagnosis. to ascertain this issue, we evaluated: * changes in receptor polymorphism (ace2 and cd26 receptor study. * sars-cov-2 cd4/cd8 t cell response (ctl) * different kir phenotypes

only 24% of health care workers (hcw) had developed inmunological response to sars cov-2 infection in one centre attending thousands of covid-19 patients, and with shorteness of personal protective equipments. our hypothesis is that this relatively low number of infected hcw could be secondary to: 1. differences in susceptibility to infection mediated by changes in viral receptors. thus, it is important to characterize and genotyping the main receptor for sars-cov-2, ace2, and other related receptor, such as cd26. 2. increased cellular immune response, offering cross-immunity against sars cov-2 infection by previous exposure to other coronavirus or respiratory pathogens. a specific cd4/cd8 t cell response to viral peptides could respond this question 3. specific kir phenotypes (killer immunoglobulin-like receptors): natural killer cells (nk) response to alterations of class i hla molecules presented in infected cells. an increase in class i hla expression could lead to an increase in nk activation by increasing its ability to produce ifn-gamma.

Eligibility criteria:
inclusion criteria * hcw older than 18 years * highly exposed to covid-19 according to the definition * negative (cases) or positive (controls) serology against sars-cov-2 infection exclusion criteria * presence of any disease / treatment which could alter the susceptibility (corticoid therapy, chemotherapy, monoclonal antibodies) * pregnancy high exposure definition: direct and continued care of covid-19 diagnosed patients for 2 weeks or more, without aerosol- generating procedures, with inappropriate personal protective equipment (ppe), or unprotected exposure to patients with covid-19 during aerosol-generating procedures. the definition of appropriate ppe was based on previous recommendations. the absence of any part of the ppe constituted an unprotected exposure. we defined the following as aerosol-generating procedures: airway suction, application of a high-flow o2 instrument, bronchoscopy, endotracheal intubation, tracheostomy, nebulizer treatment, sputum induction, positive pressure ventilation, manual ventilation and cardiopulmonary resuscitation.

Keywords: coronavirus, susceptibility, transmission, hcw
to evaluate the food effect on relative bioavailability of rp6530 in healthy volunteers

Conditions: Healthy

Summary: this is a single centre, open label, randomized, two-treatment, two-period, two-sequence, single dose crossover food effect study in 18 subjects. the subjects will receive the study medication under either fed or fast during each treatment period.

the present study will be conducted in healthy male volunteers. a single oral dose will be administered to the subject in each treatment period (under either fasting or fed state). each treatment period will be separated by at least 7 calendar days. post dose pk blood samples will be collected in each treatment period to evaluate the food effect on bioavailability of rp6530. the safety and tolerability of single dose will also be evaluated.

Eligibility criteria:
inclusion criteria: * healthy male volunteers; aged 18 to 45 years; * body mass index (bmi) between 18.0 and 30.0 kg/m2 inclusive, weight ≥ 50 kg; * non- smokers or ex-smokers; * able to give informed consent. exclusion criteria: * subjects with evidence or history of clinically significant disease; * positive results to hiv ag/ab combo, hepatitis b surface antigen (hbsag (b) (hepatitis b)) or hepatitis c virus (hcv (c)) tests; * subjects who have received any investigational drug in the previous 28 days; * subjects participated in a study with pi3k inhibitors at least once in past year; * subjects who have received drugs metabolised by cyp3a4 enzyme in the previous 28 days.

Keywords: fasting fed condition pharmacokinetics
spanish cohort for the study of the effect of cpap in hypertension (cepecta)

Conditions: Sleep Apnea; Hypertension

Summary: aims:to know the effects of the treatment with nasal positive continuous airway pressure (cpap) on systemic blood pressure and the expression of biological mediators, in systemic hypertension of recent diagnostic, whose have an apnea-hypopnea index \> 15. methodology: design: prospective, multicenter, randomized study, of parallel groups and controlled with placebo, in patients diagnosed of systemic hypertension (sh) with an apnea-hypopnea index, by conventional polysomnography \> 15. a total of 340 patients with recently diagnosed of sh and without any pharmacological treatment will be studied. all patients will be randomized to receive, alternatively, cpap treatment with optimal pressure titled with a proved system, or sham-cpap for 12 weeks. measurements: a) conventional polysomnography at baseline: b) clinic: sleepiness (ats, basic nordic sleep questionnaire and epworth), quality of life (euroqol); c) 24 hour blood pressure monitoring; d) expression of biological mediators in blood: general determinations, endothelial, inflammatory, lipid, renin-angiotensin-aldosterone and adrenergic mediators. analysis. baseline measurements of all the variables will be compared with the situation at six and twelve weeks. we will use the chi square test and the fisher´s exact test (categorical variables), the t test for continous variables and repeated measures ancova for the primary objective. the analyses will be done under the criterion of intention to treat and for protocol. the variables will be controlled by the compliance with the cpap..


Eligibility criteria:
inclusion criteria: * patients, both sexes from 18 to 75 years old, with clinical suspected of osah defined by an apnea-hypopnea index \> 15 and having a recent diagnosis of hypertension which have not received any pharmacological treatment for hypertension. exclusion criteria: inclusion criteria: * patients with clinical suspected of osah defined by an apnea-hypopnea index \> 15 and having a recent diagnosis of hypertension which have not received any pharmacological treatment for hypertension. exclusion criteria: * severe excessive daytime sleepiness; professional drivers; pregnant women; alcohol consumption more than 100 gr. ethanol per day; sedative medication; psychiatric illness; malignant or complicated hypertension; renal insufficiency; severe chronically ilness or malignant ilness; severe craniomandibular disease

Keywords: sleep apnea hypertension cpap
evaluation of clinical decision support system for scoring of aspect score using brain ct images

Conditions: Ischemic Stroke

Summary: caspects is a software that has been pre-learned based on aspects score of ischemic stroke patients using brain ct images, and clinical decision support system for scoring aspects score by automatically analyzing brain ct images by assisting the medical team. the specific aims of this study are to evaluate efficacy of caspects for scoring aspects score compared to the sensitivity and specificity levels of human expert.


Eligibility criteria:
inclusion criteria: * adults over 19 years old * brain ct acquired exclusion criteria: * patients with ischemic stroke in posterior circulation * poor or incomplete brain ct image quality